


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/23/04

Signature:

(Signature)
(Ginny Blundell)

Docket No.: JMY-P01-001
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Chervonsky et al.

Application No.: 10/777883

Confirmation No.: 6714

Filed: February 12, 2004

Art Unit: 1614

For: METHODS OF MODULATING HOMING
OF T CELL BY INTERRUPTION OF
CHEMOKINE/CHEMOKINE RECEPTOR
SIGNALING

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of the non U.S. references on the PTO/SB/08 are attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent,

publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. JMY-P01-001.

Dated: November 23, 2004

Respectfully submitted,

By 

Z. Angela Guo

Registration No.: 54,144

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|-------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/777883 |
| | | | | Filing Date | February 12, 2004 |
| | | | | First Named Inventor | Alexander V. Chervonsky |
| | | | | Art Unit | 1614 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 1 | of | 2 | Attorney Docket Number | JMY-P01-001 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A1 | 6,153,441 | 11/28/00 | Appelbaum, et al. | |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--|-----------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B1 | WO 92/01810 | | 2/6/92 | Michael Lerner | |
| | B2 | WO 02/20615 A2 | | 3/14/02 | MICROMET AG | |
| | | | | | | |
| | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | |
| | C1 | Baekkevold et al., "The CCR7 ligand ELC (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment," J. Exp. Med. 193:1105-1111, 2001. | | |
| | C2 | Baggiolini et al., "Human Chemokines: An Update," Annu. Rev. Immunol. 15:675-705, 1997. | | |
| | C3 | Campbell et al., "Chemokines and the arrest of lymphocytes rolling under flow conditions," Science, 279:381-384, 1998. | | |
| | C4 | Chen et al., "Ectopic expression of the murine chemokines CCL21a and CCL21b induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice," J. Immunol., 168:1001-1008, 2002. | | |
| | C5 | Constantin et al., "Chemokines trigger immediate beta 2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow," Immunity, 13:759-769, 2000. | | |
| | C6 | Delovitch et al., "The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD," Immunity, 7:727-738, 1997. | | |
| | C7 | Elices et al., "VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site," Cell 60:577-584, 1990. | | |
| | C8 | Fan et al., "Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis," J. Immunol., 164:3955-3959, 2000. | | |
| | C9 | Gunn et al., "Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization," J. Exp. Med., 189:451-460, 1999. | | |
| | C10 | Hjelmstrom et al., "Lymphoid tissue homing chemokines are expressed in chronic inflammation," Am. J. Pathol., 156:1133-1138, 2000. | | |
| | C11 | Kreisel et al., "Nonhematopoietic allograft cells directly activate CD8 ⁺ T cells and trigger acute rejection: an alternative mechanism of allorecognition," Nat. Med., 8:233-239, 2002. | | |
| | C12 | Limmer et al., "Efficient presentation of exogenous antigen by liver endothelial cells to CD8 ⁺ T cells results in antigen-specific T-cell tolerance," Nat. Med. 12:1348-1354, 2000. | | |
| | C13 | Luther et al., "BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin- | | |

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|-------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/777883 |
| | | | | Filing Date | February 12, 2004 |
| | | | | First Named Inventor | Alexander V. Chervonsky |
| | | | | Art Unit | 1614 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 2 | of | 2 | Attorney Docket Number | JMY-P01-001 |

| | | | |
|--|-----|---|--|
| | | dependent lymphoid neogenesis," Immunity, 12:471-481, 2000. | |
| | C14 | Ngo et al., "Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells," J. Exp. Med., 188:181-191, 1998. | |
| | C15 | Pober et al., "Human endothelial cell presentation of antigen and the homing of memory/effector T cells to skin," Ann. NY Acad. Sci. 941:12-25. | |
| | C16 | Savinov et al., "Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8 ⁺ T cells," J. Exp. Med. 197:643-656, 2003. | |
| | C17 | Sebastiani et al., "Chemokine receptor expression and function in CD4 ⁺ T lymphocytes with regulatory activity," J. Immunol. 166:996-1002, 2001. | |
| | C18 | Serreze, et al., "Major histocompatibility complex class I-deficient NOD-B2m ^{null} mice are diabetes and insulinitis resistant," Diabetes, 43:505-509, 1994. | |
| | C19 | Shimizu et al., "Regulated expression and binding of three VLA (beta 1) integrin receptors on T cells," Nature, 345:250-253, 1990. | |
| | C20 | Stein et al., "The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6CKine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules," J. Exp. Med., 191:61-75, 2000. | |
| | C21 | Tisch et al., "Insulin-dependent diabetes mellitus," Cell 85:291-297, 1996. | |
| | C22 | Toyoda et al., "Contribution of T cells to the development of autoimmune diabetes in the NOD mouse model," BioEssays, 20:750-757, 1998. | |
| | C23 | Valujskikh et al., "Cross-primed CD8 ⁺ T cells mediate graft rejection via a distinct effector pathway," Nat. Immunol., 3:844-851, 2002. | |
| | C24 | von Andrian et al., "T-cell function and migration. Two sides of the same coin." N. Engl. J. Med., 343:1020-1034, 2000. | |
| | C25 | Wong et al., "Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2K ^d that stimulates CD8 T cells in insulin-dependent diabetes mellitus," PNAS, 99:5551-5556, 2002. | |
| | C26 | Wong et al., "CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells," J. Exp. Med., 183:67-76, 1996. | |
| | C27 | Wong et al., "Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library," Nat. Med., 5:1026-1031, 1999. | |
| | C28 | Wong et al., "The role of CD4 vs. CD8 T cells in IDDM," J. Autoimmune., 13: 290-295, 1999. | |
| | C29 | Yoshie et al., "Novel lymphocyte-specific CC chemokines and their receptors," J. Leukocyte Biol. 62:634-644, 1997. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.